Kornimate/medical-research-clean huggingface dataset:
investigating idiopathic pulmonary fibrosis in greece

Conditions: Idiopathic Pulmonary Fibrosis

Summary: to gain further insight on the characteristics, management, disease progression and the outcomes of patients with ipf, as diagnosed and treated under real-world, clinical practice conditions in greece. more specifically, this registry will be used to: provide a comprehensive clinical picture of ipf, track access to health care and cost of caring for ipf patients over time, examine the implementation of treatment guidelines used on patients diagnosed with ipf, according to the existing diagnosis guidelines, characterization of patients on different treatments. to provide information regarding survival and mortality causes, ipf exacerbations as well as ipf patient co-morbidities including myocardial infarction, cns infarction, other arterial thromboembolic events, deep vein thrombosis, hemorrhage, gastrointestinal perforation and pulmonary hypertension. data regarding ipf patient hospitalization will be collected and evaluated with regards to potential respiratory causes, and there will be documentation of treatment patterns and economic aspects. patients will be followed up for 2 years and information regarding ipf treatment changes since the last visit will be collected.

purpose: to gain further knowledge on the characteristics, management, progression and outcomes of patients with ipf as treated under real-world, clinical practice conditions in greece study design: national, multi-center, observational disease registry based on new data from a significant sample size of ipf patients in greece. patients will be followed up for 2 years and information will be collected during this time period. this is a non-interventional study and primary data collected during study visits will be used

Eligibility criteria:
inclusion criteria: * newly diagnosed (less than 6 months) or patients previously diagnosed with ipf (more than 6 months from baseline visit), based upon the consensus statement jointly issued by ats/ers/jrs/alat in 2011 (see annexes 6 and 7 for hrct and histological criteria in annex 6) * exclusion of other known causes of ild (e.g., domestic and occupational environmental exposures, connective tissue disease, and drug toxicity) * assessment of ipf based on hrct or combinations of hrct and surgical lung biopsy, if available * age =40 years old at the time of inclusion * written informed consent for participation in the registry * patients that can be followed up further, during the scheduled study period exclusion criteria: * expected lung transplantation within the following 6 months * participation in clinical trials
full bladder iud insertion without vulsellum under ultrasound guidance

Conditions: Contraceptive Device

Summary: the aim of this study is to determine whether full bladder iud insertion without vulsellum or uterine sound under ultrasound guidance is associated with less pain compared with the standard technique of iud insertion .

the intrauterine device (iud) is an effective method of contraception. pain experienced during iud insertion is one of the main causes that limits its widespread use. pain during iud insertion is caused by insertion of cusco vaginal speculum, sounding the uterus, application of vulsellum to grasp the cervix, the passage of the inserter tube through the cervical canal and uterine cavity.. in order to minimize the pain associated with iud insertion , several studies reported that the use of ultrasound to guide the insertion of iud into uterine cavity was associated with less pain and more accurate placement of iud, other studies reported that filling the bladder during iud insertion minimized the pain associated with iud insertion.

Eligibility criteria:
inclusion criteria: * women requesting iud insertion exclusion criteria: * active pelvic infection * viable intrauterine pregnancy * uterine anomalies * uterine fibroid * wilson disease

Keywords: iud ultrasound full bladder pain
nozin in preventing respiratory viral infections in patients undergoing stem cell transplant, prev-nose study

Conditions: Hematopoietic and Lymphoid Cell Neoplasm; Malignant Solid Neoplasm; Solid Neoplasm

Summary: this phase i trial studies the side effects of nozin in preventing respiratory viral infections in patients undergoing stem cell transplant. nozin is a non-antibiotic, alcohol-based nasal sanitizer used in hospitals to prevent spread of bacterial infections and may also prevent community acquired respiratory virus infection in stem cell transplant recipients.

outline: patients are randomized to 1 of 2 arms. arm i: beginning 7 days prior to transplant, patients receive nozin via nasal single-use popswabs or single-use cotton tipped applicators and swab the inside of their nose two times daily (bid) up to 100 days after transplant. arm ii: patients receive standard of care. after completion of study, patients are followed up every week for 6 weeks and then every alternate week until day 100.

Eligibility criteria:
inclusion criteria: * undergoing allogeneic hematopoietic transplant for malignant or non-malignant disease * english speaking * capable of providing informed consent * planned to receive follow-up at the transplant site for the first 100 days post transplantation * subjects who the investigator believes can and will comply with the study protocol exclusion criteria: * documented respiratory viral infection in the two weeks prior to enrollment * current or planned use of any prophylactic antiviral therapy, antibody treatments, or other agents targeting the prevention of respiratory viruses (i.e. oseltamivir, ribavirin, amantadine) * known allergy to study drug components (jojoba, orange oil, coconut oil, lauric acid, benzalkonium chloride, vitamin e) * receiving oxygen supplementation at time of enrollment * active mucositis at time of enrollment * ongoing irritation or active infection of the squamous epithelial cell skin involving the nose or nasal vestibule * daily use of nasal decontamination products or other nasal medications (e.g. nasal steroids) * unable to complete study procedures (e.g. nasal swab self-testing)
intravitreal injections by nurses and physicians compared

Conditions: Eye Diseases

Summary: anti-vegf agents are given for a variety of previously untreatable eye diseases. the last years indications for their use and consequently the number of patients needing treatment, have been increasing. most patients require multiple injections. this has resulted in many eye departments administering thousands of injections per year, also at st olavs university hospital trondheim. to cope with this increase in workload, it would be helpful if injections would be given not only by the physicians but also by the nurses. this study's objective is to compare efficiency, patient satisfaction and cost per patient of injections given by nurses and physicians.


Eligibility criteria:
inclusion criteria: * referred to the eye clinic for treatment of age related macular degeneration, diabetes retinopathy or retinal vein occlusion with anti-vascular endothelium growth factor * ability to provide written informed consent * ability to comply with study assessments for the full duration of the study exclusion criteria: -

Keywords: intravitreal injections nurses physicians
evaluation of adjunctive injectable prf therapy used in conjunction with scaling and root planning

Conditions: Periodontal Pockets

Summary: clinical evaluation of local administration of injectable prf (injectable platelet-rich fibrin) in periodontal pockets as adjunctive therapy to scaling and root planing. 15 periodontal patients will receive a through traditional mechanical treatment (scaling and root planing). each patient will receive subgingival i-prf injected in half mouth and the opposite side will be injected with saline, immediately after the deep scaling session.

the aim of the study is to evaluate the efficacy of i-prf subgingival injection right after scaling and root planing as adjunctive therapy to traditional mechanical therapy. 15 periodontal patients will receive traditional mechanical supra and subgingival scaling and root planing. i-prf will be applied subgingivally in the deep pockets in a half mouth design. the injected half mouth (study group) for each patient will be allocated randomly. the opposite side will be injected with saline (control group). clinical parameters will be evaluated: plaque index (pi), bleeding on probing (bop), probing depth (pd), clinical attachment level (cal). clinical measurements will be performed at baseline and at 8 weeks.

Eligibility criteria:
inclusion criteria: * patients are in general good health. * patients are from both gender and are adult. * a sign informed consent from participation and permission to use obtained data for research purposes. * they have not taken medication known to interfere with periodontal tissue health or healing in the preceding 6 months. * presence of bilateral periodontal pockets (≥5 mm) on the minimum of 2 teeth in each side. exclusion criteria: * patients less than 18 years' old * immunosuppressive systemic diseases (like cancer, aids, diabetes...) * clotting and hematological disorders * medications influence on the gingival and periodontal tissues (like calcium channel blockers, or long-term steroid use * the teeth with poor bad filling and poorly fitted restorations

Keywords: periodontal pockets injectable platelet-rich fibrin saline
carotid doppler and ivc measurements for volume guided management in acute kidney injury patients

Conditions: Acute Kidney Injury

Summary: 1. evaluate inferior vena cava indices (diameters , ivc-ci)\&carotid doppler measurements (corrected carotid flow time ,carotid blood flow ,carotid artery peak velocity variations) as non-invasive technique for volume guided management in aki patient. 2. estimate correlation between ivc (diameters , ivc-ci) \& carotid doppler measurements (corrected carotid flow time ,carotid blood flow ,carotid artery peak velocity variations) as non-invasive technique for volume guided management in aki patient.

acute kidney injury affects increasing numbers of patients worldwide, it was estimated approximately 15% of all subjects treated in hospitals develop acute kidney injury,even a small increase in serum creatinine may be associated with increased risk of mortality , oliguric aki it imposes a great challenge for fluid management. recently, ultrasonography for estimating volume status has been widely recommended because of its non-invasive nature, ease of acquisition, and reproducibility of measurements.among these ultrasound modalities, ultrasonographic assessment of the inferior vena cava \& carotid doppler measurements . in spontaneously breathing patients, the inferior vena cava (ivc) diameter and the ivc collapsibility index (ivc-ci) have been shown to correlate with the volume status and central venous pressure (cvp) . also has been shown to indicate fluid status in children , ventilated patients and healthy volunteers . corrected carotid flow time (cft) unaffected by respiration predicting fluid responsiveness that has shown promising results.studies to date have shown that corrected cft increases in response to fluid administration or consumption , and decreases in response to volume removal in dialysis and blood donation .

Eligibility criteria:
inclusion criteria: 1. patients diagnosed with acute kidney injury 2. age must be more than 18 years exclusion criteria: 1. morbid obesity (bmi \>35) 2. end stage renal disease (esrd) on dialysis 3. sever ventricular dysfunction, valvular heart disease 4. carotid stenosis \>50% 5. chronic obstructive pulmonary disease. 6. pregnancy \& tense ascites
sequential treatment with ro-mtx after pomalidomide, orelabrutinib, rituximab (por) in newly-diagnosed pcnsl

Conditions: Primary Central Nervous System Lymphoma

Summary: this is a multicenter prospective single arm phase ii study, and the purpose of this study is to evaluate the safety and efficacy of sequential treatment regimens with ro-mtx after pomalidomide, orelabrutinib, rituximab (por) in newly-diagnosed primary central nervous system lymphoma, and explore the feasibility of chemo-free treatment in pcnsl. the primary objective was the overall response rate (orr; defined as partial response \[pr\] or better) after 4 cycles of por.

there are 2 sections of this trial. step1: the patients will be treated with 4 cycles of por regimen （pomalidomide 4mg d1-d14, orelabrutinib 150mg d1-d21, rituximab 375mg/m2 d1, 21 days per cycle). the response will be evaluated every 2 cycles. the patients with pd will drop out of the study. step2: patients with cr/pr/sd after 4 cycles of por treatment will be treated with 2 cycles of ro-mtx regimen（methotrexate 3.5g/m2 civ d1, orelabrutinib 150mg d1-d21, rituximab 375mg/m2 d1, 21 days per cycle). after 6 cycles of induction therapy, all patients were followed for survival data every 12 week until disease progression, disease recurrence, death, or study termination. patients with progression were also followed up for survival data as above. overall survival will be followed up to 3 years after the last subject entered the study. establishing the feasibility of chemo-free treatment in primary central nervous system lymphoma will provide the foundation for a larger study of efficacy and long-term outcomes of chemo-free therapy for patients with pcnsl.

Eligibility criteria:
inclusion criteria: * • newly diagnosed primary central nervous system lymphoma * pathological type is b cell lymphoma * age 18-70 years * demonstrate adequate marrow hemopoietic function as defined below:wbc\>3.0×109/l,anc\>1.5×109/l,hgb\>90g/l,plt\>80×109/l * demonstrate adequate organ function as defined below: cardiac function grade 0-2（nyha）；spo2\>88%( natural state)；alt\ 60ml/min/m2 * having at least one measurable lesions * sign the informed consent exclusion criteria: * • the pathological diagnosis was t-cell lymphoma. * systemic lymphoma involved cns * pre-existing uncontrolled active infection * acute myocardial infarction or unstable angina within 6 months; uncontrolled hypertension and arrhythmia * active bleeding * allergic to any component of the investigational product. * subjects who are suspected to be unable to comply with the study protocol * pregnancy or active lactation

Keywords: orelabrutinib pomalidomide rituximab primary central nervous system lymphoma methotrexate
celsius tcs hyperthermia system pmcf trial

Conditions: Solid Neoplasms

Summary: based on the basic data of all patients foreseen for a local hyperthermia in the participating centers the failure rate (of the celsius tcs hyperthermia system) and the complication rate (injury to the patients) will be recorded.

during this pmcf trial from each participating center the internal data of all celsius tcs hyperthermia devices are collected. the participating centers are obligated to report any device-related failure and adverse event (injury to the patient). the center reports together with the device-internal data allows to calculate the failure and the complication rates. it will be analyzed regarding the kind of tumor and the concomitant treatment (radiotherapy and/or chemotherapy). the outcome groups (with/without failure or complication) will be analyzed regarding demographic and treatment parameters.

Eligibility criteria:
inclusion criteria: * treatment performed with the celsius tcs hyperthermia system exclusion criteria: * not applicable -

Keywords: neoplasms hyperthermia
effect of nortriptyline in cortical representation of heartburn in nonerosive reflux disease (nerd) patients

Conditions: Gastroesophageal Reflux Disease

Summary: patients with nonerosive reflux disease (nerd) are less responsive to standard treatment with proton pump inhibitors. the hypothesis of this study was that nortriptyline in analgesic doses may decrease heartburn perception and its corresponding cortical activity measured by magnetic resonance image. therefore, the aim of this study was to assess the cortical representation of heartburn in patients with nerd under treatment with nortriptyline and placebo.


Eligibility criteria:
inclusion criteria: * more than 17 years old, heartburn at least twice a week, naive to antireflux medications and antidepressive agents exclusion criteria: * active esophagitis at endoscopy, contraindications to nortriptyline use

Keywords: reflux disease heartburn
evaluation of the influence of prf (platelet-rich fibrin) on the clinical parameters and the concentration of selected inflammation mediators in gcf (gingival crevice fluid) of patients with periodontitis

Conditions: Periodontal Disease; Periodontitis

Summary: assessment of the influence of injectable platelet-rich fibrin (i-prf) on the clinical parameters and the inflammation mediators levels in the gingival crevicular fluid (gcf) in patients with periodontitis.

forty subjects diagnosed with periodontitis were randomly divided into two groups. in the test group, srp was performed with the subsequent application of iprf into periodontal pockets, while in the control group srp was performed alone. clinical examination was performed before and 1, 3 and 6 months after treatment. for inflammation mediators levels determination in gcf samples elisa method will be used.

Eligibility criteria:
inclusion criteria: * clinical and radiological features of periodontitis in stage ii, iii or iv * presence of at least 4 teeth and at least 2 pockets (localized not on the same tooth) with a depth of at least 5 mm in each quadrant exclusion criteria: * periodontal treatment within 3 months prior to the study; * antibiotic therapy within 3 months prior to the study; * smoking; presence of systemic diseases affecting periodontal healing, i.e.: immunosuppressive diseases, diabetes, osteoporosis, aids, hypertension treated with calcium channel blockers; * use of steroids or other immunosuppressive drugs; * coagulation disorders and use of drugs affecting its mechanisms; * pregnant and breastfeeding women

Keywords: periodontitis srp prf
effectiveness of a treatment plan of neurological physiotherapy in conjunction with ultrasound-guided ultrasound-guided dry needling in stroke patients.

Conditions: Neurological Disorder

Summary: the aim of the study is to assess the efficacy of dry needling in stroke patients in combination with intensive neurological physiotherapy. together with intensive neurological physiotherapy treatment. randomised and blinded experimental study control group where the sample recruited was 20 patients, who were randomly assigned to a control group. randomly assigned to a control group, where they received intensive treatment, or to an intervention group, where they received intervention group, where they received ultrasound-guided dry needling of the tibialis anterior and posterior muscles followed by an intensive followed by intensive neurological physiotherapy treatment.


Eligibility criteria:
inclusion criteria: * left middle cerebral artery infarction * impaired stability during walking * patient between the age range 18 to 70 years old exclusion criteria: * patient under 18 years of age * patients over 70 years of age * undiagnosed left middle cerebral artery infarction patients

Keywords: dry needling physiotherapy techniques anterior tibial muscle posterior tibial muscle neurological disorder
beflubu vs fluburux conditioning in haploidentical hct

Conditions: Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Biphenotypic Acute Leukemia; Lymphoblastic Lymphoma; Myeloproliferative Neoplasm; Myelodysplastic Syndromes

Summary: haploidentical hematopoietic stem cell transplantation irrespective of the conditioning intensity and graft-versus-host disease prophylaxis is associated with high frequency of primary and secondary graft failure. different technologies of with replete or depleted graft are associated with 7-20% of graft failures in different diseases. fludarabine and busulfan conditioning is the most commonly used approach for a variety of diseases. in two previously completed trials of addition of either bendamustine and ruxolitinib to conditioning we observed low rates of primary graft failure with both approaches. the study is the direct randomized comparisons of these two approaches with the primary aim of reducing composite events of primary graft failure, relapse and non-relapse mortality. the stratas for the study are disease risk index (dri) and the age of the haploidentical donor (\<35 vs ≥35).


Eligibility criteria:
inclusion criteria: * patients must have an indication for allogeneic hematopoietic stem cell transplantation with myeloablative conditioning for malignant disease * diagnosis: acute myeloid leukemia, acute lymphoblastic leukemia, mixed lineage acute leukemia, lymphoblastic lymphoma, chronic myeloid leukemia, myelodysplastic syndromes, myeloprolipherative neoplasm * age ≥18 * malignant disease in hematologic response: \<5% of clonal blasts in the bone marrow and no clonal blasts in peripheral blood. * patients with 5-9/10 hla-matched related donor available. the donor and recipient must be identical by the following genetic loci: hla-a, hla-b, hla-cw, hla-drb1, and hla-dqb1. * peripheral blood stem cells or bone marrow as a graft source exclusion criteria: * titer of anti-donor anti-hla antibodies ≥ 5000 at the time of inclusion * moderate or severe cardiac disease: ejection fraction \<50%, unstable angina, stable angina nyha class iii or iv, chronic heart failure nyha class iii or iv, lawn grade v arrhythmia, myocardial infarction within 3 months before inclusion * stroke within 3 months of inclusion, unless related to the underlying malignancy * severe decrease in pulmonary function: fev1 \<50% or dlco\<50% of predicted or respiratory distress or need for oxygen support; * severe organ dysfunction: ast or alt \>5 upper normal limits, bilirubin \>1.5 upper normal limits, creatinine \>2 upper normal limits * creatinine clearance \< 40 ml/min * uncontrolled bacterial or fungal infection at the time of enrollment defined by crp\> 70 mg/l * requirement for vasopressor support at the time of enrollment * karnofsky index \<70% * pregnancy * somatic or psychiatric disorder making the patient unable to sign informed consent
accelerated itbs for depression: monitoring brain hemodynamics with simultaneous itbs/fnirs

Conditions: Depression

Summary: this study will investigate the cortical hemodynamic response variability of an accelerated form of tbs stimulation over left dorsolateral prefrontal cortex (dlpfc) using a concurrent tbs/fnirs setup. the accelerating tms protocol that will be used in this study is similar to the stanford accelerated intelligent neuromodulation therapy (saint), i.e., fifty itbs sessions (1,800 pulses per session, 50-minute intersession interval) will be delivered as 10 daily sessions over 5 consecutive days at 90% resting motor threshold. the investigators will recruit a depressed patient and conduct a concurrent itbs/fnirs protocol for each itbs session. moreover, the depression symptoms of the patient will be assessed before and after treatment.


Eligibility criteria:
inclusion criteria: * aged 18 to 65; * a clinical diagnosis of current nonpsychotic major depressive disorder by an experienced psychiatrist according to dsm-iv; * no or stable (≥2 weeks) psychopharmacological medication; * have not responded to at least one antidepressant medication; * have not received any tms treatment; * and have a 17-item hamd score ≥ 20. exclusion criteria: * severe internal diseases; * neurological disorders or a history of severe head injuries; * having suicidal ideation; * pregnancy; * common mri, fnirs and tms exclusion criteria, such as a history of brain surgery, head injury, cardiac pacemaker, deep brain stimulation, intracranial metallic particles, history of seizures * antiepileptics and benzodiazepines corresponding to a dose of \>1 mg lorazepam/d.

Keywords: theta-burst stimulation (itbs) functional near-infrared spectroscopy (fnirs) concurrent tms/fnirs prefrontal hemodynamic response